Neumora Therapeutics
NMRA · NASDAQ · Health Care · Biological Products, (No Diagnostic Substances)
Biological Products, (No Diagnostic Substances) company based in Watertown, Ma.
Example public filing
10% owner bought ~$5M
ARCH Venture Partners X, 10% owner at Neumora Therapeutics, bought ~$5M of Neumora Therapeutics shares.
- ~$5M
- Approx. value · 1.92M sh @ $2.61
- 6.05M
- Holds after · shares reported
- Traded
- Oct 27, 2025
- Filed
- Oct 29, 2025
Data as of Oct 11, 2026. A real record from the official source, chosen as the most recent insider trade or, failing that, the most recent filing of another kind; not a recommendation.
On file for NMRA, last 12 months
- 66
- Insider filings
- 0
- Congress trades
- 2
- Fund positions
- 0
- Federal contracts
Records OQRO holds, counted by their date; a 13F position is counted once per quarter it is reported.
Insider buying and selling since 2023
Insiders of Neumora Therapeutics reported 44 open-market purchases and 32 sales since 2023; purchases in 2 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | 15×15 trades |
| 2025 | 3×3 trades | 6×6 trades |
| 2024 | — | 11×11 trades |
| 2023 | 41×41 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. The amounts, the people and every filing are in OQRO Pro.
See the full picture with OQRO Pro.
68 records for Neumora Therapeutics in the last 12 months, each linked to its filing. Full histories, the screener, alerts for the companies you follow and Ask OQRO.
Latest disclosures
Secure payment by Stripe. Renews every month until you cancel; cancel anytime from your account. No free trial.
Public previews are free. Full research requires Pro. No free trial.
What this page holds
- Insider trades and planned sales
- Politician trades (House and Senate)
- Fund holdings from 13F filings
- Federal contracts, lobbying and short selling
- Full history and context, with a link to every filing
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
Questions about Neumora Therapeutics insider trading
Have Neumora Therapeutics insiders bought shares recently?
No open-market purchase by an insider of Neumora Therapeutics was filed in the last 90 days. The latest on record was on Oct 29, 2025.
How often do Neumora Therapeutics insiders buy and sell shares?
Since 2023, Neumora Therapeutics insiders reported 44 open-market purchases and 32 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2025.
Do members of Congress trade NMRA?
No trade in Neumora Therapeutics (NMRA) was disclosed by a member of Congress in the last 12 months.
When does Neumora Therapeutics report its next results?
Neumora Therapeutics's next results are expected on Nov 4, 2026. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.